Dragan Jevremovic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3253783/publications.pdf

Version: 2024-02-01

66 papers 2,831 citations

28 h-index 52 g-index

66 all docs

66 docs citations

66 times ranked 3658 citing authors

#	Article	IF	CITATIONS
1	Diverse Origin and Function of Cells With Endothelial Phenotype Obtained From Adult Human Blood. Circulation Research, 2003, 93, 1023-1025.	4.5	424
2	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, 2019, 15, 45-59.	9.6	330
3	Autologous Culture-Modified Mononuclear Cells Confer Vascular Protection After Arterial Injury. Circulation, 2003, 108, 1520-1526.	1.6	168
4	Validation of cellâ€based fluorescence assays: Practice guidelines from the ICSH and ICCS – part V – assay performance criteria. Cytometry Part B - Clinical Cytometry, 2013, 84, 315-323.	1.5	153
5	A Balance between Positive and Negative Signals in Cytotoxic Lymphocytes Regulates the Polarization of Lipid Rafts during the Development of Cell-Mediated Killing. Journal of Experimental Medicine, 2000, 191, 347-354.	8.5	119
6	SLP-76 Is a Direct Substrate of SHP-1 Recruited to Killer Cell Inhibitory Receptors. Journal of Biological Chemistry, 1998, 273, 27518-27523.	3.4	116
7	Diagnosis and Management of Waldenström Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	7.1	110
8	Interference of CD40L-Mediated Tumor Immunotherapy by Oncolytic Vesicular Stomatitis Virus. Human Gene Therapy, 2010, 21, 439-450.	2.7	74
9	Atrophic Autoimmune Pangastritis: A Distinctive Form of Antral and Fundic Gastritis Associated With Systemic Autoimmune Disease. American Journal of Surgical Pathology, 2006, 30, 1412-1419.	3.7	70
10	Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer Journal, 2017, 7, e584-e584.	6.2	68
11	Regulation of NK Cell-Mediated Cytotoxicity by the Adaptor Protein 3BP2. Journal of Immunology, 2001, 166, 7219-7228.	0.8	64
12	Cystic nephroma (multilocular cyst) and mixed epithelial and stromal tumor of the kidney: a spectrum of the same entity?. Annals of Diagnostic Pathology, 2006, 10, 77-82.	1.3	62
13	Disseminated Mycobacterium chimaera Infection After Cardiothoracic Surgery. Open Forum Infectious Diseases, 2016, 3, ofw131.	0.9	58
14	Gene Therapy to Manipulate Effector T Cell Trafficking to Tumors for Immunotherapy. Journal of Immunology, 2005, 174, 5766-5773.	0.8	54
15	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood, 2017, 129, 82-87.	1.4	50
16	Treg Depletion–enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic Virus. Molecular Therapy, 2008, 16, 1217-1226.	8.2	47
17	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. Biology of Blood and Marrow Transplantation, 2017, 23, 598-605.	2.0	47
18	Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1037-1046.	4.5	46

#	Article	IF	Citations
19	Single Antibody Detection of Tâ€Cell Receptor αβ Clonality by Flow Cytometry Rapidly Identifies Mature Tâ€Cell Neoplasms and Monotypic Small CD8â€Positive Subsets of Uncertain Significance. Cytometry Part B - Clinical Cytometry, 2020, 98, 99-107.	1.5	45
20	T-cell clones of uncertain significance are highly prevalent and show close resemblance to T-cell large granular lymphocytic leukemia. Implications for laboratory diagnostics. Modern Pathology, 2020, 33, 2046-2057.	5.5	40
21	Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer Journal, 2016, 6, e512-e512.	6.2	38
22	Enhancing the Râ€ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. American Journal of Hematology, 2020, 95, 310-315.	4.1	37
23	The expression of the novel cytotoxic protein granzyme M by large granular lymphocytic leukaemias of both T-cell and NK-cell lineage: an unexpected finding with implications regarding the pathobiology of these disorders. British Journal of Haematology, 2007, 137, 237-239.	2.5	36
24	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. American Journal of Hematology, 2020, 95, 497-502.	4.1	35
25	Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy. Gene Therapy, 2003, 10, 1663-1671.	4.5	34
26	Chronic lymphoproliferative disorder of natural killer cells: a distinct entity with subtypes correlating with normal natural killer cell subsets. Leukemia, 2010, 24, 881-884.	7.2	32
27	CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma. Leukemia Research, 2010, 34, 1235-1238.	0.8	30
28	Flow Cytometry Applications in the Diagnosis of T/NKâ€Cell Lymphoproliferative Disorders. Cytometry Part B - Clinical Cytometry, 2019, 96, 99-115.	1.5	30
29	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. Haematologica, 2017, 102, 1439-1445.	3.5	29
30	Flow cytometric evaluation of <scp>TRBC1</scp> expression in tissue specimens and body fluids is a novel and specific method for assessment of <scp>Tâ€cell</scp> clonality and diagnosis of <scp>Tâ€cell</scp> neoplasms. Cytometry Part B - Clinical Cytometry, 2021, 100, 361-369.	1.5	29
31	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 13-16.	3.0	25
32	LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma. American Journal of Clinical Pathology, 2016, 145, 180-190.	0.7	23
33	T-Cell Large Granular Lymphocytic Leukemia and Coexisting B-Cell Lymphomas. American Journal of Clinical Pathology, 2018, 149, 164-171.	0.7	23
34	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Advances, 2018, 2, 3149-3154.	5.2	23
35	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances, 2020, 4, 2236-2244.	5.2	20
36	Utility of TRBC1 Expression in the Diagnosis of Peripheral Blood Involvement by Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 2021, 141, 821-829.e2.	0.7	19

#	Article	lF	CITATIONS
37	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. American Journal of Hematology, 2019, 94, 751-756.	4.1	15
38	Single-Antibody Evaluation of T-Cell Receptor \hat{l}^2 Constant Chain Monotypia by Flow Cytometry Facilitates the Diagnosis of T-Cell Large Granular Lymphocytic Leukemia. American Journal of Clinical Pathology, 2021, 156, 139-148.	0.7	15
39	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2018, 24, 2360-2364.	2.0	14
40	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. American Journal of Hematology, 2019, 94, E117-E120.	4.1	13
41	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. American Journal of Hematology, 2020, 95, 637-642.	4.1	12
42	Molecular Diagnosis of Hematopoietic and Lymphoid Neoplasms. Hematology/Oncology Clinics of North America, 2009, 23, 903-933.	2.2	11
43	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiâ€parametric flow cytometry method. American Journal of Hematology, 2019, 94, 424-430.	4.1	11
44	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. Blood Cancer Journal, 2021, 11, 43.	6.2	11
45	Plasmacytoma of the Temporal Bone, a Great Imitator: Report of Seven Cases and Comprehensive Review of the Literature. Otology and Neurotology, 2017, 38, 400-407.	1.3	10
46	Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma $\hat{a}\in$ " tissue remains the issue. Leukemia and Lymphoma, 2017, 58, 2342-2348.	1.3	10
47	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica, 2018, 103, 1229-1234.	3.5	10
48	Flow Cytometric Evaluation of Surface and Cytoplasmic TRBC1 Expression in the Differential Diagnosis of Immature T-Cell Proliferations. American Journal of Clinical Pathology, 2022, 157, 64-72.	0.7	10
49	Loss of Blast Heterogeneity in Myelodysplastic Syndrome and Other Chronic Myeloid Neoplasms. American Journal of Clinical Pathology, 2014, 142, 292-298.	0.7	9
50	Germline <i>SH2B3</i> pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. American Journal of Hematology, 2019, 94, E231-E234.	4.1	9
51	Prevalence and spectrum of T-cell lymphoproliferative disorders in patients with Hypereosinophilia: A reference laboratory experience. Annals of Diagnostic Pathology, 2020, 44, 151412.	1.3	9
52	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia, 2018, 32, 1421-1426.	7.2	8
53	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. Bone Marrow Transplantation, 2019, 54, 442-447.	2.4	7
54	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood Cancer Journal, 2021, 11, 122.	6.2	7

#	Article	IF	CITATIONS
55	Increased incidence of endometrioid tumors caused by aberrations in E-cadherin promoter of mismatch repair-deficient mice. Carcinogenesis, 2011, 32, 1085-1092.	2.8	5
56	Decreased normal NK-cells is a characteristic of T-cell large granular lymphocytic leukemia and is strongly associated with cytopenia. Leukemia and Lymphoma, 2016, 57, 1230-1233.	1.3	5
57	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. American Journal of Hematology, 2017, 92, E507-E512.	4.1	5
58	Isolated anemia in patients with large granular lymphocytic leukemia (LGLL). Blood Cancer Journal, 2022, 12, 30.	6.2	4
59	Flow Cytometric Assessment of Chronic Myeloid Neoplasms. Clinics in Laboratory Medicine, 2017, 37, 803-819.	1.4	3
60	Cytoplasmic Expression of CD3ε Heterodimers by Flow Cytometry Rapidly Distinguishes Between Mature T-Cell and Natural Killer–Cell Neoplasms. American Journal of Clinical Pathology, 2020, 154, 683-691.	0.7	3
61	Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndrome. British Journal of Haematology, 2020, 190, 79-83.	2.5	3
62	Immunophenotypic and laboratory features of $t(11;14)(q13;q32)$ -positive plasma cell neoplasms. Leukemia and Lymphoma, 2018, 59, 1913-1919.	1.3	2
63	Characteristics of patients with myelodysplastic syndrome with balanced translocations. British Journal of Haematology, 2020, 190, 244-248.	2.5	1
64	Clinical characteristics and outcomes of ocular adnexal mantle cell lymphoma. Orbit, 2022, 41, 97-104.	0.8	1
65	Lymphoma-like double-hit genetic abnormalities (<i>MYC/IGH</i> and <i>IGH/BCL2</i>) in a case of non-secretory multiple myeloma. Leukemia and Lymphoma, 2021, 62, 243-246.	1.3	O
66	Laboratory Work-Up of Chronic B-Cell Lymphoid Malignancies – A Value-Based Approach. Acta Medica Academica, 2019, 48, 45.	0.8	0